Squarepoint’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Squarepoint’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-23,187	Closed	-$61.7K	–	4821
2024 Q1	$61.7K	Sell	23,187 -35,650	-61%	-$88.3K	﹤0.01%	3859
2023 Q4	$139K	Sell	58,837 -17,212	-23%	-$30.5K	﹤0.01%	3694
2023 Q3	$106K	Sell	76,049 -72,166	-49%	-$173K	﹤0.01%	3553
2023 Q2	$449K	Buy	+148,215	New	+$571K	﹤0.01%	2684
2023 Q1	–	Sell	-25,091	Closed	-$153K	–	3952
2022 Q4	$153K	Buy	+25,091	New	+$204K	﹤0.01%	2869
2022 Q2	–	Sell	-14,064	Closed	-$158K	–	3535
2022 Q1	$158K	Buy	+14,064	New	+$155K	﹤0.01%	2533
2021 Q3	–	Sell	-13,272	Closed	-$309K	–	3576
2021 Q2	$309K	Buy	+13,272	New	+$338K	﹤0.01%	2508

Squarepoint's KNTE Position: Q2 2024 in Review

Squarepoint sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 23,187 shares — an estimated $61.7K sold.

Squarepoint first reported a position in KNTE in Q2 2021 and held it in 7 quarters. The position peaked at $449K in Q2 2023. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Squarepoint reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Squarepoint sold 23,187 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $61.7K.
Squarepoint first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2021 and held it in 7 quarters.
Squarepoint's Kinnate Biopharma Inc. Common Stock position peaked at $449K in Q2 2023.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Squarepoint's 13F filing for Q2 2024, filed 14 Aug 2024.